EVLO vs. SCPS, VAXX, CMRA, GNCA, ARDS, CALA, AMPE, CLVR, EFTR, and PXMD
Should you be buying Evelo Biosciences stock or one of its competitors? The main competitors of Evelo Biosciences include Scopus BioPharma (SCPS), Vaxxinity (VAXX), Comera Life Sciences (CMRA), Genocea Biosciences (GNCA), Aridis Pharmaceuticals (ARDS), Calithera Biosciences (CALA), Ampio Pharmaceuticals (AMPE), Clever Leaves (CLVR), eFFECTOR Therapeutics (EFTR), and PaxMedica (PXMD). These companies are all part of the "pharmaceutical products" industry.
Evelo Biosciences vs.
Evelo Biosciences (NASDAQ:EVLO) and Scopus BioPharma (NASDAQ:SCPS) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, profitability, earnings, valuation, community ranking, institutional ownership, analyst recommendations, dividends and risk.
In the previous week, Evelo Biosciences had 2 more articles in the media than Scopus BioPharma. MarketBeat recorded 2 mentions for Evelo Biosciences and 0 mentions for Scopus BioPharma. Evelo Biosciences' average media sentiment score of 0.32 beat Scopus BioPharma's score of 0.00 indicating that Evelo Biosciences is being referred to more favorably in the media.
Evelo Biosciences has a beta of 1.54, suggesting that its share price is 54% more volatile than the S&P 500. Comparatively, Scopus BioPharma has a beta of -0.19, suggesting that its share price is 119% less volatile than the S&P 500.
Evelo Biosciences received 168 more outperform votes than Scopus BioPharma when rated by MarketBeat users. However, 100.00% of users gave Scopus BioPharma an outperform vote while only 60.50% of users gave Evelo Biosciences an outperform vote.
0.3% of Evelo Biosciences shares are owned by institutional investors. 1.0% of Evelo Biosciences shares are owned by insiders. Comparatively, 5.1% of Scopus BioPharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Summary
Evelo Biosciences beats Scopus BioPharma on 5 of the 8 factors compared between the two stocks.
Get Evelo Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for EVLO and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Evelo Biosciences Competitors List
Related Companies and Tools
This page (NASDAQ:EVLO) was last updated on 2/22/2025 by MarketBeat.com Staff
